Impact of Intravitreal Anti-VEGF Therapy on Microperimetry of the Retinal Nonperfusion Areas of Patients with Proliferative Diabetic Retinopathy

[1] Yau JW(2012)Global prevalence and major risk factors of diabetic retinopathy Diabetes Care 35 556-564

[2] Rogers SL(2015)Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss Eye Vis (Lond) 2 17-2203

[3] Kawasaki R(2017)Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial Lancet 389 2193-200

[4] Lee R(2017)Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections Clin Ophthalmol 21 193-802

[5] Wong TY(2013)Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion Ophthalmology 120 795-634

[6] Sabanayagam C(2016)Changes in retinal nonperfusion associated with suppression of vascular endothelial growth factor in retinal vein occlusion Ophthalmology 123 625-34

[7] Sivaprasad S(2017)Optical coherence tomography angiography analysis of the foveal avascular zone and macular vessel density after anti-VEGF therapy in eyes with diabetic macular edema and retinal vein occlusion Invest Ophthalmol Vis Sci 58 30-434

[8] Prevost AT(2019)Anti-vascular endothelial growth factor therapy can improve diabetic retinopathy score without change in retinalperfusion Retina 39 426-1694

[9] Vasconcelos JC(2019)Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti vascular endothelial growth factor Ophthalmology 126 1685-135

[10] Levin AM(2011)Microperimetry in diabetic retinopathy Saudi J Ophthalmol 25 131-3051

[1] Yau JW(2012)Global prevalence and major risk factors of diabetic retinopathy Diabetes Care 35 556-564

[2] Rogers SL(2015)Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss Eye Vis (Lond) 2 17-2203

[3] Kawasaki R(2017)Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial Lancet 389 2193-200

[4] Lee R(2017)Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections Clin Ophthalmol 21 193-802

[5] Wong TY(2013)Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion Ophthalmology 120 795-634

[6] Sabanayagam C(2016)Changes in retinal nonperfusion associated with suppression of vascular endothelial growth factor in retinal vein occlusion Ophthalmology 123 625-34

[7] Sivaprasad S(2017)Optical coherence tomography angiography analysis of the foveal avascular zone and macular vessel density after anti-VEGF therapy in eyes with diabetic macular edema and retinal vein occlusion Invest Ophthalmol Vis Sci 58 30-434

[8] Prevost AT(2019)Anti-vascular endothelial growth factor therapy can improve diabetic retinopathy score without change in retinalperfusion Retina 39 426-1694

[9] Vasconcelos JC(2019)Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti vascular endothelial growth factor Ophthalmology 126 1685-135

[10] Levin AM(2011)Microperimetry in diabetic retinopathy Saudi J Ophthalmol 25 131-3051